Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FSCN1 | Q16658 | 1/20 | 0.65 |
| ▸ | PTGER4 | P35408 | 7/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.41 |
| ▸ | CPT1A | P50416 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30695057 | 1.00 | FSCN1 (0.65) | FSCN1PTGER4ADORA3PTGDR2P2RY14 | |
| SCHEMBL17199349 | 0.89 | FSCN1 (0.50) | FSCN1PTGER4HDAC3HDAC1HDAC2 | |
| SCHEMBL20442238 | 0.86 | FSCN1 (0.51) | FSCN1PTGER4ADORA3PTGDR2P2RY14 | |
| SCHEMBL30695044 | 0.84 | FSCN1 (0.69) | FSCN1PTGER4PTGDR2P2RY14HDAC3 | |
| SCHEMBL17039034 | 0.84 | FSCN1 (0.69) | FSCN1PTGER4PTGDR2P2RY14HDAC3 | |
| SCHEMBL17039037 | 0.83 | FSCN1 (0.70) | FSCN1PTGER4ADORA3PTGDR2P2RY14 | |
| SCHEMBL30695118 | 0.83 | FSCN1 (0.70) | FSCN1PTGER4ADORA3PTGDR2P2RY14 | |
| SCHEMBL17038972 | 0.83 | FSCN1 (0.76) | FSCN1PTGER4ADORA3PTGDR2P2RY14 | |
| SCHEMBL30695030 | 0.83 | FSCN1 (0.76) | FSCN1PTGER4ADORA3PTGDR2P2RY14 | |
| SCHEMBL17028016 | 0.81 | FSCN1 (0.70) | FSCN1PTGER4PTGDR2P2RY14HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124449-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | NOVITA PHARMACEUTICALS, INC. (US) | 2024-04-18 | — | — | US | disclosed |
| US-11858929-B2 | Compounds and methods for inhibiting fascin | CORNELL UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858929-B2 | Compounds and methods for inhibiting fascin | CORNELL UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858929-B2 | Compounds and methods for inhibiting fascin | CORNELL UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230310378-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | NOVITA PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230310378-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | NOVITA PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | US | disclosed |
| US-11701342-B2 | Co-therapies including a metastasis inhibitor | CORNELL UNIVERSITY (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701342-B2 | Co-therapies including a metastasis inhibitor | CORNELL UNIVERSITY (US) | 2023-07-18 | — | — | US | disclosed |
| US-20210340138-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | NOVITA PHARMACEUTICALS, INC. | 2021-11-04 | — | — | US | disclosed |
| US-20210340138-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | NOVITA PHARMACEUTICALS, INC. | 2021-11-04 | — | — | US | disclosed |
| US-20170158692-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY | 2017-06-08 | — | — | US | disclosed |
| US-20170158692-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY | 2017-06-08 | — | — | US | disclosed |
| US-20170158692-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY | 2017-06-08 | — | — | US | disclosed |
| US-9573946-B2 | Compounds and methods for inhibiting fascin | NOVITA PHARMACEUTICALS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573946-B2 | Compounds and methods for inhibiting fascin | NOVITA PHARMACEUTICALS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573946-B2 | Compounds and methods for inhibiting fascin | NOVITA PHARMACEUTICALS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20150299191-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY | 2015-10-22 | — | — | US | disclosed |
| US-20150299191-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY | 2015-10-22 | — | — | US | disclosed |
| US-20150299191-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY | 2015-10-22 | — | — | US | disclosed |
| WO-2015127125-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY (US) | 2015-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124449-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | FSCN1, MTPN, MYOF | FSCN1 1/4885PTGER4 4107/4885ADORA3 4451/4885 |
| US-20150299191-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | FSCN1, MTPN, MYOF | FSCN1 1/4885PTGER4 4107/4885ADORA3 4451/4885 |
| US-20210340138-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | FSCN1, MTPN, MYOF | FSCN1 1/4885PTGER4 4107/4885ADORA3 4451/4885 |
| US-11858929-B2 | Compounds and methods for inhibiting fascin | FSCN1, MTPN, MYOF | FSCN1 1/4885PTGER4 4107/4885ADORA3 4451/4885 |
| US-20230310378-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | MIF, CXCL10, CCL2 | FSCN1 1017/4885PTGER4 4560/4885ADORA3 3860/4885 |
| US-20170158692-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | FSCN1, MTPN, MYOF | FSCN1 1/4885PTGER4 4107/4885ADORA3 4451/4885 |
| US-11701342-B2 | Co-therapies including a metastasis inhibitor | MIF, CXCL10, CCL2 | FSCN1 1017/4885PTGER4 4560/4885ADORA3 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.